Abstract
Both diet and medications are useful in the treatment of the obese patient. Weight loss of about 10% below baseline can be achieved with both, and there is no evidence that the composition of the diet, by itself, has any influence on weight loss. Presently only 1 drug is approved for long-term treatment of overweight patients, and its effectiveness is limited to palliation of the chronic disease of obesity. Combinations of medications and antidiabetic drugs that produce weight loss are being evaluated.
MeSH terms
-
Adolescent
-
Adult
-
Anti-Obesity Agents / adverse effects
-
Anti-Obesity Agents / pharmacology
-
Anti-Obesity Agents / therapeutic use*
-
Antidepressive Agents, Second-Generation / therapeutic use
-
Body Weight / drug effects
-
Bupropion / therapeutic use
-
Child
-
Drug Approval
-
Drug Combinations
-
Energy Intake / drug effects
-
Exenatide
-
Female
-
Fructose / analogs & derivatives
-
Fructose / therapeutic use
-
Humans
-
Hypoglycemic Agents / pharmacology
-
Hypoglycemic Agents / therapeutic use*
-
Islet Amyloid Polypeptide / therapeutic use
-
Lactones / pharmacology
-
Lactones / therapeutic use
-
Male
-
Metformin / therapeutic use*
-
Naltrexone / therapeutic use
-
Narcotic Antagonists / therapeutic use
-
Obesity / drug therapy*
-
Obesity / metabolism
-
Orlistat
-
Patient Compliance
-
Peptides / therapeutic use
-
Randomized Controlled Trials as Topic
-
Sympathomimetics / adverse effects
-
Sympathomimetics / therapeutic use
-
Topiramate
-
Vereinigte Staaten
-
United States Food and Drug Administration
-
Venoms / therapeutic use
Substances
-
Anti-Obesity Agents
-
Antidepressive Agents, Second-Generation
-
Drug Combinations
-
Hypoglycemic Agents
-
Islet Amyloid Polypeptide
-
Lactones
-
Narcotic Antagonists
-
Peptides
-
Sympathomimetics
-
Venoms
-
Bupropion
-
Topiramate
-
Fructose
-
Naltrexone
-
Metformin
-
Orlistat
-
Exenatide
-
pramlintide